Gene therapy shot for dry AMD shows early promise in small trial
Disease control
Terminated
This study tested a single injection of a gene therapy called GT005 in 56 people with dry age-related macular degeneration (AMD), a leading cause of vision loss. The goal was to check safety and find the right dose. The trial was stopped early, but the results help researchers un…
Phase: PHASE1, PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC